Print（PDF/103KB） Aug. 20, 2012 Corporate

Dainippon Sumitomo Pharma announces organizational changes:Establishment of the "DSP Cancer Institute"

Osaka, Japan, August 20, 2012 - Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo Tada) announces today that it will establish a new organization specializing in the oncology area called the "DSP Cancer Institute".

There has been rapid scientific progress in the research and development of oncology in recent years. Additionally, in this area of high unmet medical needs, more pharmaceutical companies are entering, making competition very intense and this means rapid, flexible decision-making is necessary. For this reason, we decided to establish the DSP Cancer Institute as an organization independent of the Research Division under direct control of the President.

In charge of the DSP Cancer Institute is the President, Chief Executive Officer, Chief Medical Officer of our U.S. subsidiary Boston Biomedical Inc. (BBI), and the Head of Global Oncology for DSP Group Chiang J. Li, M.D. At the same time as the new establishment of the DSP Cancer Institute, the functions of the existing Global Oncology Business Development Office have been strengthened to provide centralized management of R&D in the oncology area, and management of the DSP Cancer Institute.

With the establishment of the new DSP Cancer Institute and the strengthening of the Global Oncology Business Development Office, we have restructured the strategic management and R&D organization of our oncology area aiming for the creation of innovative anti-cancer drugs.

In addition, within 2012 BBI plans to establish a Global Oncology R&D Center in Cambridge Massachusetts, U.S., with a scale of 100 employees.